Clinical Trials Browser

OTHER × Adenocarcinoma Of Esophagus × Nivolumab × Clear all

NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Phase 2 Recruiting

DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT05480384 2026-04-21

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05476796 2024-10-24

LOGICAN

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms